As of Friday close, Aldeyra Therapeutics Inc.’s (NASDAQ:ALDX) stock was up $0.68, moving up 10.90 percent to $6.92. The average number of shares traded per day over the past five days has been 1,371,280 shares. 5 times new highs have been achieved over the past 5 days, with a $1.88 gain in that time frame. In the last twenty days, the average volume was 1,154,165, while in the previous 50 days, it was 1,152,610.
Since last month, ALDX stock rose 59.45%. Shares of the company fell to $4.02 on 07/06/22, the lowest level in the past month. A 52-week high of $10.19 was reached on 08/05/22 after having rallying from a 52-week low of $2.36. Since the beginning of this year, ALDX’s stock price has risen by 73.00% or $2.92, and marked a new high 11 times. However, the stock has declined by -32.09% since its 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Aldeyra Therapeutics Inc. (ALDX) last reported insider trading activity 3 days ago on Aug 03. PERCEPTIVE ADVISORS LLC, the 10% Owner of the company, purchased of 100,000 shares for $5.84 on Aug 03. It resulted in a $584,000 investment by the insider. PERCEPTIVE ADVISORS LLC added 412,406 shares at an average price of $5.59 on Aug 02. The insider now owns 10,801,985 shares following the transaction. On Aug 01, 10% Owner PERCEPTIVE ADVISORS LLC bought 144,185 shares at $5.05 apiece. The transaction was valued at $728,134.
In the three months ended March 30, Aldeyra Therapeutics Inc.’s quick ratio stood at 13.60, while its current ratio was 13.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.08, and the total debt-to-equity ratio was 0.08. Based on annual data, ALDX earned $1.74 million in gross profit and brought in $56.22 million in revenue.
In Aldeyra Therapeutics Inc.’s quarter-end financial report for March 30, it reported total debt of $15.59 million against cash and short-term investments of $57.96 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Aldeyra Therapeutics Inc. to report -$0.31 quarterly earnings, the actual figure was -$0.29 per share, beating the consensus estimate by 6.50%. During the quarter, the company generated -$16.34 million in EBITDA. The liabilities of Aldeyra Therapeutics Inc. were 32.0 million at the end of its most recent quarter ended March 30, and its total debt was $15.89 million. The value of shareholders’ equity is $58.3 million.
This quick technical analysis looks at Aldeyra Therapeutics Inc.’s (ALDX) price momentum. With a historical volatility rate of 58.52%, the RSI 9-day stood at 88.37% on 05 August.
With respect to its five-day moving average, the current Aldeyra Therapeutics Inc. price is up by +37.30% percent or $1.88. At present, ALDX shares trade +54.12% above its 20-day simple moving average and +84.53% percent above its 100-day simple moving average. However, the stock is currently trading approximately +157.25% above its SMA50 and -17.72% below its SMA200.
Stochastic coefficient K was 88.91% and Stochastic coefficient D was 85.28%, while ATR was 0.49. Given the Stochastic reading of 82.34% for the 14-day period, the RSI (14) reading has been calculated as 82.85%. As of today, the MACD Oscillator reading stands at 0.79, while the 14-day reading stands at 0.95.
Aldeyra Therapeutics Inc. (ALDX) has been rated Buy by analysts. According to 0 brokerage firms, ALDX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Aldeyra Therapeutics Inc. stock as buy, with 8 recommending it as overweight.